Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53

B. Akpinar, EV. Bracht, D. Reijnders, B. Safarikova, I. Jelinkova, A. Grandien, AH. Vaculova, B. Zhivotovsky, M. Olsson,

. 2015 ; 6 (41) : 43679-97.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000887

Despite recent advances in targeted therapeutics, administration of 5-fluorouracil (5-FU) remains a common clinical strategy for post-surgical treatment of solid tumors. Although it has been proposed that RNA metabolism is disturbed by 5-FU treatment, the key cytotoxic response is believed to be enzymatic inhibition of thymidylate synthase resulting in nucleotide pool disproportions. An operating p53 tumor suppressor signaling network is in many cases essential for the efficiency of chemotherapy, and malfunctions within this system remain a clinical obstacle. Since the fate of chemotherapy-insensitive tumor cells is rarely described, we performed a comparative analysis of 5-FU toxicity in p53-deficient cells and conclude that p53 acts as a facilitator rather than a gatekeeper of cell death. Although p53 can act as a regulator of several cellular stress responses, no rerouting of cell death mode was observed in absence of the tumor suppressor. Thus, the final death outcome of 5-FU-treated p53-/- cells is demonstrated to be caspase-dependent, but due to a slow pace, accumulation of mitochondrial reactive oxygen species contributes to necrotic characteristics. The oligomerization status of the p53 target gene DR5 is determined as a significant limiting factor for the initiation of caspase activity in an intracellular TRAIL-dependent manner. Using several experimental approaches, we further conclude that RNA-rather than DNA-related stress follows by caspase activation irrespectively of p53 status. A distinct 5-FU-induced stress mechanism is thereby functionally connected to a successive and discrete cell death signaling pathway. Finally, we provide evidence that silencing of PARP-1 function may be an approach to specifically target p53-deficient cells in 5-FU combinatorial treatment strategies. Together, our results disclose details of impaired cell death signaling engaged as a consequence of 5-FU chemotherapy. Obtained data will contribute to the comprehension of factors restraining 5-FU efficiency, and by excluding DNA as the main stress target in some cell types they propose alternatives to currently used and suggested synergistic treatment regimens.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000887
003      
CZ-PrNML
005      
20170103130314.0
007      
ta
008      
170103s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.6030 $2 doi
024    7_
$a 10.18632/oncotarget.6030 $2 doi
035    __
$a (PubMed)26544897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Akpinar, Birce $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. $7 gn_A_00003037
245    10
$a 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53 / $c B. Akpinar, EV. Bracht, D. Reijnders, B. Safarikova, I. Jelinkova, A. Grandien, AH. Vaculova, B. Zhivotovsky, M. Olsson,
520    9_
$a Despite recent advances in targeted therapeutics, administration of 5-fluorouracil (5-FU) remains a common clinical strategy for post-surgical treatment of solid tumors. Although it has been proposed that RNA metabolism is disturbed by 5-FU treatment, the key cytotoxic response is believed to be enzymatic inhibition of thymidylate synthase resulting in nucleotide pool disproportions. An operating p53 tumor suppressor signaling network is in many cases essential for the efficiency of chemotherapy, and malfunctions within this system remain a clinical obstacle. Since the fate of chemotherapy-insensitive tumor cells is rarely described, we performed a comparative analysis of 5-FU toxicity in p53-deficient cells and conclude that p53 acts as a facilitator rather than a gatekeeper of cell death. Although p53 can act as a regulator of several cellular stress responses, no rerouting of cell death mode was observed in absence of the tumor suppressor. Thus, the final death outcome of 5-FU-treated p53-/- cells is demonstrated to be caspase-dependent, but due to a slow pace, accumulation of mitochondrial reactive oxygen species contributes to necrotic characteristics. The oligomerization status of the p53 target gene DR5 is determined as a significant limiting factor for the initiation of caspase activity in an intracellular TRAIL-dependent manner. Using several experimental approaches, we further conclude that RNA-rather than DNA-related stress follows by caspase activation irrespectively of p53 status. A distinct 5-FU-induced stress mechanism is thereby functionally connected to a successive and discrete cell death signaling pathway. Finally, we provide evidence that silencing of PARP-1 function may be an approach to specifically target p53-deficient cells in 5-FU combinatorial treatment strategies. Together, our results disclose details of impaired cell death signaling engaged as a consequence of 5-FU chemotherapy. Obtained data will contribute to the comprehension of factors restraining 5-FU efficiency, and by excluding DNA as the main stress target in some cell types they propose alternatives to currently used and suggested synergistic treatment regimens.
650    _2
$a protinádorové antimetabolity $x farmakologie $7 D000964
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a fluorescenční protilátková technika $7 D005455
650    _2
$a fluoruracil $x farmakologie $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a imunoblotting $7 D015151
650    _2
$a imunoprecipitace $7 D047468
650    _2
$a transmisní elektronová mikroskopie $7 D046529
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a RNA $x účinky léků $7 D012313
650    _2
$a signální transdukce $x účinky léků $x fyziologie $7 D015398
650    _2
$a protein TRAIL $x metabolismus $7 D053221
650    _2
$a transdukce genetická $7 D014161
650    _2
$a nádorový supresorový protein p53 $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bracht, Ethiene V $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Reijnders, Dorin $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Safarikova, Barbora $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
700    1_
$a Jelinkova, Iva $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
700    1_
$a Grandien, Alf $u Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital-Huddinge, Stockholm, Sweden.
700    1_
$a Vaculova, Alena Hyrslova $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
700    1_
$a Zhivotovsky, Boris $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Olsson, Magnus $u Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 6, č. 41 (2015), s. 43679-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26544897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170103130401 $b ABA008
999    __
$a ok $b bmc $g 1180027 $s 961454
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c 41 $d 43679-97 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...